Summary of Osai Kang's Conference Call Company Overview - Osai Kang started as a traditional PPI (Proton Pump Inhibitor) business and expanded into biopharmaceutical innovation since 2012, focusing on oncology and infectious diseases. The company has diversified its dosage forms from injectables to oral and sustained-release formulations. The strategy involves parallel development of generic and innovative drugs, where generics ensure cash flow and innovative drugs support valuation [2][3][4]. Key Business Segments - **Generic Drugs**: Osai Kang has made significant progress in the generic drug sector since 2021, with multiple products approved, contributing to revenue growth. The impact of centralized procurement is expected to diminish by 2024, leading to stable performance. The company focuses on first generics and difficult-to-generate products, leveraging integrated raw material and formulation advantages to reduce costs and enhance competitiveness [2][6]. - **Innovative Drugs**: The company is concentrating on oncology, infectious diseases, and chronic diseases, with several products entering clinical trials. Notable products include: - **Third-generation EGFR TKI small molecule inhibitors** for lung cancer, which, despite a slower development pace, are expected to achieve good sales due to strong academic promotion capabilities from partners. - **Colo 80.2 monoclonal antibody** for lung and gastric cancer, with only four similar products in Phase III trials in China, indicating a competitive edge [2][7]. Financial and Market Position - The actual controllers of Osai Kang are Chen Qingcai and his wife. Key subsidiaries include: - **Nanjing Hairong Pharmaceutical**: Raw material production base with cost advantages. - **Nanjing Haiguang Applied Chemistry Research Institute**: Main generic drug R&D base. - **AskGin**: An overseas subsidiary responsible for biopharmaceutical innovation, in which Osai Kang holds a 60% stake [2][4][5]. Product Highlights - **SKB589**: A leading 18.2 monoclonal antibody triple therapy showing an objective response rate (OR) of 80%, indicating best-in-class potential. The progression-free survival (PFS) data is also promising, showcasing significant advantages over competitors like AstraZeneca, which uses a dual therapy approach [2][9]. - **Maifen Capsule**: An oral iron supplement that combines the convenience of traditional oral supplements with the efficacy of intravenous options while minimizing gastrointestinal side effects. This product is expected to capture significant market share in both hospital and outpatient settings [2][10]. - **VEGFR2 Dual-target Ophthalmic Drug**: Targeting AMD and DME, this drug extends the dosing interval to 4-5 months or even six months, significantly improving patient convenience. It is currently in Phase 2B clinical trials, with Phase 3 expected to start in 2026 [2][11]. Future Directions - Osai Kang aims to maintain a dual strategy of ensuring stable cash flow through first generics and difficult generics while actively advancing innovative drug development for higher market returns. The company plans to strengthen international collaborations to enhance R&D capabilities and expand into emerging markets [2][8]. Upcoming Catalysts - Important data releases are anticipated in the coming months, including updates on SKB589's overall survival (OS) data at the ISMO conference in October and preliminary data for interleukin-15 dual antibodies by the end of the year. Additionally, AstraZeneca's Phase II data for its 18.2 monoclonal antibody targeting pancreatic cancer will be closely monitored as potential catalysts for Osai Kang's stock price [2][13].

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The 2025 World Conference on Lung Cancer (WCLC) highlighted the promising clinical data of domestic lung cancer drugs, particularly the innovative drug iza-bren developed by BaiLi Tianheng, which demonstrated a 100% objective response rate (ORR) in first-line patients with EGFR mutation non-small cell lung cancer (NSCLC) [2][17] - The report suggests a favorable outlook for the pharmaceutical sector, particularly in innovative drugs, research services, and CXO [3][12] Summary by Sections Industry Performance - The A-share pharmaceutical index has seen a year-to-date increase of 26.8%, while the Hang Seng Biotechnology Index has surged by 103.3% [11] - Notable stock performances include Zhend Medical (+41.3%) and Haooubo (+28.0%), while Yuekang Pharmaceutical (-18.4%) and Maiwei Biological (-14.4%) faced significant declines [11] New Drug Developments - Novartis' lung cancer drug, Capmatinib, received approval for a new indication in China, and Johnson & Johnson initiated a Phase III clinical trial for its KLK2/CD3 dual antibody [2] - BaiLi Tianheng's iza-bren showed a 100% ORR in a Phase II study for EGFR mutation NSCLC, with a median progression-free survival (mPFS) of 12.5 months [17][21] Investment Recommendations - The report ranks preferred sub-sectors as follows: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [3][12] - Specific companies to watch include: - From GLP-1 perspective: BoRui Pharmaceutical, GeLi Pharmaceutical, and XinDa Biologics - From PD-1/VEGF dual antibody perspective: Kangfang Biologics and Shenzhou Cell - From AI drug development perspective: JingTai Holdings and Chengdu XianDao [3][12] Clinical Research Updates - The HARMONi study by Kangfang Biologics showed improved overall survival (OS) with a hazard ratio (HR) of 0.78, indicating a significant benefit for patients, especially in North America [25] - The report emphasizes the ongoing clinical trials for innovative drugs, including the registration Phase III study for iza-bren [20][24]

Core Viewpoint - A Chinese innovative drug, iza-bren, has received breakthrough therapy designations from both the FDA and the Chinese regulatory authority, showcasing its potential in lung cancer treatment with a remarkable objective response rate (ORR) of 100% in clinical trials [3][18]. Group 1: Clinical Data and Breakthroughs - The Phase II clinical trial of iza-bren combined with Osimertinib for EGFR-mutant non-small cell lung cancer (NSCLC) reported an ORR of 100%, the highest recorded for first-line treatments in this category [4][8]. - The trial included 154 patients, with the 2.5 mg/kg dose group showing significant efficacy, leading to the selection of this dosage for future Phase III studies [11][12]. - The median progression-free survival (PFS) rate at 12 months was 92.1%, and the overall survival (OS) rate was 94.8%, indicating strong potential for long-term benefits [10][18]. Group 2: Challenges and Solutions - The drug addresses significant challenges in lung cancer treatment, such as tumor heterogeneity and resistance, with a 100% ORR suggesting a breakthrough in overcoming these issues [9][14]. - The median tumor shrinkage was nearly 57%, indicating substantial tumor reduction, which lays a solid foundation for long-term disease control [9][10]. Group 3: Future Research and Development - The Phase III clinical trial has been initiated, focusing on the efficacy and safety of iza-bren combined with Osimertinib compared to Osimertinib alone, with primary endpoints including PFS and secondary endpoints covering OS and safety [11][12]. - The collaboration with BMS (Bristol-Myers Squibb) is aimed at leveraging their global clinical development expertise to enhance the trial's design and execution [13][20]. Group 4: Market Position and Recognition - Iza-bren has been recognized as a "First-in-class" and "New concept" drug, marking a significant advancement for Chinese innovative pharmaceuticals in the global market [20]. - The drug's breakthrough therapy designations from both the FDA and the Chinese regulatory authority are expected to expedite its development and approval processes, potentially benefiting a large patient population [18][20].

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [6] Core Insights - The report highlights the promising clinical data of BaiLi Tianheng's EGFR/HER3 dual antibody ADC, iza-bren, for treating EGFR mutation lung cancer, which shows potential for further clinical advancement [2][3][20][21][23] Summary by Sections Weekly New Drug Market Review - From September 8 to September 14, 2025, the top five gainers in the new drug sector were: - Saintno Pharmaceutical (+32.00%) - Junshengtai (+23.73%) - Canaan Bio (+20.43%) - Rongchang Bio (+16.52%) - Hengrui Medicine (+11.91%) - The top five losers were: - Basestone Pharmaceuticals (-18.90%) - Laika Pharmaceuticals (-18.12%) - Gilead Sciences (-16.93%) - Maiwei Bio (-14.41%) - Yifang Bio (-12.46%) [1][15] Recommended Stocks to Watch - The report suggests focusing on several potential catalysts in the sector, including academic conferences, business development realizations, and insurance negotiations. Key stocks to watch include: 1. Potential overseas licensed MNC heavyweights: - Differentiated GLP-1 assets: Zhongsheng Pharmaceutical, Gilead Sciences, Borui Pharmaceutical, Kangyuan Pharmaceutical - Upgraded PD-1 products: Kangfang Bio and other PD-1/VEGF assets, Innovent Biologics - Breakthroughs in autoimmune fields: Yifang Bio, China Antibody - Innovative target ADCs: Fuhong Hanlin, Shiyao Group 2. MNC-certified products with high overseas volume certainty: - Upgraded PD-1 products: Sanofi Pharmaceutical - GLP-1 assets: Lianbang Pharmaceutical - ADC assets: Kelong Botai, BaiLi Tianheng 3. Products likely to benefit from insurance negotiations and innovative drug directories [2][20] New Drug Industry Focus Analysis - At the recent 2025 World Lung Cancer Conference (WCLC), BaiLi Tianheng presented results from two studies on its EGFR×HER3 dual antibody ADC, iza-bren, showing excellent clinical data in both first-line and second-line treatments for advanced or metastatic EGFR mutation NSCLC. The results indicate a promising future for its application in relevant indications [2][20][21] New Drug Approval and Acceptance Status - No new drug or new indication applications were approved this week, but seven new drug or new indication applications were accepted [3][25] Clinical Application Approval and Acceptance Status - This week, 41 new drug clinical applications were approved, and 46 new drug clinical applications were accepted [9][28]

Market Overview - The A-share market showed structural activity driven by policy expectations and technology themes, with the Wind All A index rising by 2.12% and the Sci-Tech 50 leading with a 5.48% increase, indicating strong market preference for technology growth sectors [2] - The communication sector performed exceptionally well due to increased demand for optical devices and higher capital expenditures from operators, while the pharmaceutical and biotechnology sector declined by 0.64%, reflecting market concerns over deepening centralized procurement policies and risks in innovative drug development [2] - The weekly performance of major indices included a 1.52% increase in the Shanghai Composite Index, a 2.65% rise in the Shenzhen Index, and a 2.10% gain in the ChiNext Index [2] Fund Issuance - A total of 39 funds were issued last week, including 18 equity funds, 13 mixed funds, 5 bond funds, and 3 FOF funds, with a total issuance of 21.794 billion units [3][17] Fund Performance - The Wind All Fund Index rose by 1.17% last week, with the ordinary equity fund index increasing by 2.13% and the mixed equity fund index rising by 2.40% [3][7] Global Asset Review - Global major asset classes performed well, with U.S. stock indices reaching historical highs, and European and Asian markets also showing positive performance [4] - The commodity market saw active trading, with COMEX gold reaching new historical highs amid expectations of multiple interest rate cuts by the Federal Reserve [4] Domestic Bond Market Review - The national bond futures index fell by 0.32%, while medium to long-term interest rates remained low after a phase of recovery [13] Industry Performance - The Wind first-level average increase was 2.05%, with 90% of the Wind top 100 concept indices rising. All sectors except biomedicine saw gains, with communication, agriculture, and electronics performing relatively well, increasing by 5.24%, 5.00%, and 4.93% respectively [2][15]

Group 1: Research Basic Information - The research object is Xiaofang Pharmaceutical, belonging to the chemical pharmaceutical industry, and the reception time was September 12, 2025. The company's reception staff included the chairman and general manager Fang Zhiguang, the board secretary and financial director Luo Xiaoxu, and the independent director Yu Wei [17] Group 2: Detailed Research Institutions - The reception object was the 2025 semi - annual performance briefing of Shanghai Stock Exchange Roadshow Center Company [20] Group 3: Main Content Innovation and R & D - Xiaofang Pharmaceutical is not limited to traditional external medicine business and has started to layout the innovative drug field, with multiple innovative drug projects in different R & D stages. The company is advancing the R & D of traditional Chinese medicine class - one new drugs, including compound Cacumen Platycladi tincture for treating various types of hair loss and compound Herba Speranskiae Tuberculatae solution for antifungal use [24][27] - The compound Herba Speranskiae Tuberculatae solution was jointly developed with Shanghai University of Traditional Chinese Medicine Affiliated Yueyang Hospital of Integrated Traditional Chinese and Western Medicine before the company's listing, and details can be found in the company's IPO prospectus [29] - The qualification for innovative drug application needs to be scientifically determined based on sufficient pharmaceutical, non - clinical, and clinical research data, and the process is rigorous and complex. The company will disclose major progress in accordance with regulations [30] Overseas Business - The company has obtained the approval number for exporting drugs to Macau, China and has realized sales there. It will gradually explore other overseas markets while being aware of challenges such as differences in national regulations, complex registration processes, localization requirements, and strict quality supervision [27] Product Sales - The company is cautious about new product sales. Once there is a clear sales plan, it will announce it in a timely manner [28] Hospital Cooperation - The company focuses on the development and cooperation of various sales channels. Its products are suitable for sales in medical institutions at all levels. It also actively promotes the industry - university - research cooperation and development of innovative drugs [29]

Core Viewpoint - The stock price of药捷安康-B (02617.HK) surged significantly, reaching a peak increase of 131.26% on September 12, closing at 192.5 HKD per share, which represents a 77.09% increase for the day, pushing its market capitalization over 70 billion HKD. The company, which went public on June 23, saw its stock price rise over 18 times from its initial offering price of 13.15 HKD [2] Group 1: Product and Clinical Trials - The surge in market value is closely linked to the company's core product, Tinengotinib (TT-00420), which received clinical approval for a Phase II trial in treating HR+ and HER2- metastatic breast cancer [2] - Tinengotinib is a unique MTK inhibitor targeting key pathways including FGFR/VEGFR, JAK, and Aurora kinases, and is in the registration clinical stage for various hard-to-treat solid tumors [3] - The product is the first and only FGFR inhibitor in the registration clinical stage for treating recurrent or refractory cholangiocarcinoma, with significant market potential projected to grow to 3.1 billion USD by 2026 [3] Group 2: Financial Performance - Despite the stock market enthusiasm, the company has not yet approved any products for sale and has reported continuous losses over the years, with cumulative losses reaching 870 million CNY from 2022 to 2024 [4] - In the first half of 2025, the company continued to incur losses, with revenue dropping by 90.4% year-on-year to 986,000 CNY and a pre-tax loss of 123 million CNY [4] - As of June 30, 2025, the company had cash and cash equivalents of only 449 million CNY, with R&D costs of 98 million CNY for the first half of the year [4] Group 3: Competition and Market Landscape - The core product faces potential competition, with at least one FDA-approved FGFR-targeting MTK inhibitor and several others in clinical stages [5] - The competitive landscape includes multiple MTK inhibitors targeting FGFR, JAK, Aurora, and VEGFR pathways, indicating a crowded market for Tinengotinib [5]

Group 1 - The core viewpoint of the news highlights a significant rebound in the A+H innovative pharmaceutical sector, with both the A-share and Hong Kong ETF for innovative drugs showing gains of over 1% [1] - The Hong Kong ETF (520880) has seen a continuous inflow of capital, attracting over 1.6 billion yuan in new investments during recent market fluctuations [1][3] - Major stocks within the Hong Kong ETF have rebounded strongly, with notable increases such as a 130% surge in the stock of Yaojie Ankang-B, which ultimately closed up 77.09% [3][4] Group 2 - The recent rebalancing of the Hong Kong ETF index has excluded CXO companies, focusing solely on innovative drug development, which is expected to enhance the index's ability to reflect industry trends accurately [5] - The index's adjustments allow for the inclusion of smaller-cap potential stocks, such as Yaojie Ankang-B, which has shown remarkable performance since its inclusion [5][6] - China's innovative drug development is gaining momentum, with the country now holding over 20% of the global pipeline for new drugs, positioning it as the second-largest in the world [6]

Core Viewpoint - The National Medical Products Administration (NMPA) has officially launched a 30-day review and approval channel for innovative drug clinical trials, aiming to expedite the approval process for eligible applications [1][2][3]. Group 1: Policy Changes - The 30-day review channel is designed for innovative drug clinical trial applications, including traditional Chinese medicine, chemical drugs, and biological products, which meet specific criteria [3][4]. - The new policy emphasizes that the leading researchers for Phase III international multi-center clinical trials should primarily be from Chinese clinical trial institutions [4][5]. - The NMPA has been continuously optimizing the clinical trial management system to promote drug innovation and development, reducing the average review time from about 50 working days to 30 [1][7]. Group 2: Impact on Drug Development - The introduction of the 30-day channel is expected to further accelerate the clinical trial process for innovative drugs, which is crucial as this phase is often the longest in new drug development [2][3]. - The approval of 43 innovative drugs in the first half of this year represents a 59% year-on-year increase, indicating a significant boost in the domestic drug development landscape [7]. - The NMPA's reforms have led to a notable increase in the efficiency of drug review processes, with some regions achieving review times as short as 18 working days [7][8]. Group 3: Industry Collaboration and Risk Management - The 30-day channel requires applicants to commit to starting clinical trials within 12 weeks of approval, which emphasizes the need for efficient collaboration among all parties involved [5][9]. - The NMPA stresses the importance of maintaining high safety standards while expediting the review process, ensuring that clinical trials adhere to existing international standards [9]. - A new guideline for risk management during the drug development process has been introduced to help manage potential risks throughout the clinical trial lifecycle [9].

Group 1 - Baiyang Pharmaceutical signed a strategic cooperation agreement with Tianjin Jikun Pharmaceutical Technology Co., Ltd. to participate in a 24% equity stake and promote the research and clinical trials of the innovative drug JK1033 for treating idiopathic pulmonary fibrosis (IPF) [1] - Jikun Pharmaceutical is focused on innovative drug development for organ fibrosis and related inflammatory/immune diseases, possessing a comprehensive R&D capability from target discovery to clinical trials [1][2] - The JK1033 project is a small molecule compound derived from traditional Chinese medicine, showing multi-target mechanisms that can intervene in key signaling pathways of pulmonary fibrosis, with clinical trials set to start in January 2025 [2] Group 2 - The cooperation is expected to leverage the strengths of both companies in R&D, manufacturing, commercialization, and capital operations in the field of organ fibrosis, enhancing Baiyang Pharmaceutical's innovative drug portfolio [3] - Baiyang Pharmaceutical reported a revenue of 3.751 billion yuan and a net profit of 163 million yuan in the first half of the year, and is accelerating the introduction of high-value innovative products [3] - The company is transitioning from a commercialization platform to an innovative pharmaceutical enterprise, driven by a dual approach of "investment incubation + commercialization" [3][4]